Plasma biomarker trajectories: Impact of AD genetic risk and clinical progression
Plasma biomarker trajectories: Impact of AD genetic risk and clinical progression
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
INTRODUCTION
We examined long‐term plasma biomarker trajectories among participants who were cognitively unimpaired and primarily middle aged at baseline and whether trajectories differed by Alzheimer's disease (AD) genetic risk and among those who developed cognitive impairment.
METHODS
Plasma amyloid beta (Aβ)42/Aβ40, phosphorylated tau...
Alternative Titles
Full title
Plasma biomarker trajectories: Impact of AD genetic risk and clinical progression
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_7b5c60bb352449ada1f04c367ad2a745
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7b5c60bb352449ada1f04c367ad2a745
Other Identifiers
ISSN
2352-8729
E-ISSN
2352-8729
DOI
10.1002/dad2.70081
